(via TheNewswire)

Company validates proprietary quantum sampling workflow, enabling representations of continuous clinical data within a quantum computing framework

Toronto, Ontario – TheNewswire - July 29, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company), today announced that it has successfully completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis (the “Platform”).

The validated workflow enables continuous probability distributions to be represented and analyzed within a quantum computing framework. The implementation was developed and evaluated using an S&P 500 company platform for hybrid quantum-classical computing. The validation supports a key component of the Platform's computational architecture and is expected to further expand its capabilities for addressing complex analytical challenges involving large-scale clinical and biomedical datasets.

Many real-world challenges in healthcare, life sciences, drug development and advanced analytics are naturally represented as continuous probability distributions.  The Platform’s proprietary methodology converts these continuous datasets into quantum-operable energy landscape representations, enabling the application of Quantum Markov Chain Monte Carlo (“ QMCMC ”) techniques while preserving the statistical characteristics of the original data.

By using the Platform, quantum dynamics generate proposed samples while a classical acceptance mechanism preserves the target probability distribution. This hybrid quantum-classical architecture enables continuous datasets to be explored through quantum-generated proposals while maintaining established statistical guarantees.

The validated workflow represents an important step toward enabling increasingly sophisticated quantum-enabled analytical capabilities as quantum computing technologies continue to evolve. The Company believes efficient representation of continuous data within quantum systems will play an increasingly important role in next-generation computational approaches for healthcare and life sciences.

The Platform is being advanced through CliniQuantum, a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which the Company holds 54.01%.

About NeuroTera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty

IR Manager

NeuroThera Labs Inc.

Telephone: +972-3-7617108

Email: michal@efraty.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," "will," "would," "may," "plans," "advances," "toward" and similar expressions, or by statements that certain actions, events or results "may," "could," "should" or "will" be taken, occur or be achieved.

Forward-looking statements in this news release include, without limitation, statements regarding: the anticipated capabilities, performance, scalability and utility of the Company's quantum platform and of the validated quantum sampling workflow; the belief that efficient representation of continuous data within quantum systems will play an increasingly important role in next-generation computational approaches for healthcare and life sciences; the expectation that quantum computing technologies will continue to evolve in a manner that supports increasingly sophisticated analytical capabilities; the applicability of the platform to clinical, biomedical and drug development datasets; the continued development of the platform through CliniQuantum; the Company's ownership interest in CliniQuantum; and the Company's business objectives, plans and strategy generally.

Forward-looking statements are based on assumptions management considers reasonable as of the date hereof, including that: internal validation results are indicative of performance at larger scale and on real-world datasets; quantum computing hardware of sufficient capability, availability and cost will exist when required; third-party hardware, cloud and technology providers will continue to make their platforms available on acceptable terms; the Company will have access to sufficient capital and qualified personnel; the Company will maintain its interest in CliniQuantum; and no material adverse change occurs in applicable regulatory, market or competitive conditions.

Forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. These include, among others: quantum computing is an emerging and unproven technology, and there is no assurance that any quantum advantage over classical methods will be achieved or that the Company's technology will be commercially viable for the Company's use cases, or achieved on any particular timeline or at all; the validation described in this news release is preliminary, was conducted internally, has not been peer-reviewed or independently verified, and may not be replicable or predictive of results at commercial scale; the platform is a research and analytics tool, is not a medical device or diagnostic, has not been reviewed or approved by Health Canada, the U.S. Food and Drug Administration or any other regulatory authority, and is not being offered for clinical use; the Company may never generate revenue from the platform; risks inherent in clinical-stage biotechnology, including that preclinical or clinical results may not be predictive of future results; dependence on third-party quantum hardware and software providers over which the Company has no control; the Company's dependence on, and relationship with, its majority shareholder; the Company's ownership interest in CliniQuantum may be diluted or otherwise change; the ability to obtain, maintain and enforce intellectual property protection; competition from better-resourced participants; the need for additional financing and the availability of financing on acceptable terms; the Company's history of losses and limited operating history; and the other risk factors disclosed in the Company's continuous disclosure filings available under its profile on SEDAR+ at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.